Immunome, Inc. (IMNM)

1d ago, source: Yahoo Finance

BOTHELL, Wash., April 05, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it ...

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

25d ago, source: Stockhouse

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful completion of its purchase of ...

Immunome Strikes Deal to Acquire Ayala’s Drug Programs

2mon ago, source: TipRanks on MSN

Immunome, Inc. has entered into an agreement to acquire AL101 and AL102 programs from Ayala Pharmaceuticals, Inc., in a ...

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

23d ago, source: Stockhouse

Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into 2026 ...

Immunome Inc Ordinary Shares

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions

29d ago, source: Yahoo Finance

Significant control over Immunome by individual investors implies ... in Immunome is 30% A look at the shareholders of Immunome, Inc. (NASDAQ:IMNM) can tell us which group is most powerful.

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

25d ago, source: Business Insider

Following the completed sale of AL102, an oral gamma secretase inhibitor in Phase 3 clinical development, and AL 101 to Immunome, Inc., Ayala’s clinical assets include aspacytarabine (BST-236 ...

Immunome Inc Ordinary Shares IMNM

7d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

22d ago, source:

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended ...

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

25d ago, source: ADVFN

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful completion of its purchase ...

Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions

29d ago, source: Yahoo Finance

Our most recent data indicates that insiders own some shares in Immunome, Inc.. It is a pretty big company, so it is generally a positive to see some potentially meaningful alignment. In this case, ...

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

23d ago, source: ADVFN

About Immunome, Inc. Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality ...